U.S. Markets closed

Trius Therapeutics publishes TR-701 results

Trius Therapeutics announced the publication of the results of multiple clinical and animal studies showing the company's experimental antibiotic, tedizolid phosphate, or TR-701, does not interact with monamine oxidase, or MAO. MAO is an enzyme involved in the regulation of neurotransmitters such as serotonin, norepinephrine and dopamine, and its inhibition can lead to serious drug-drug interactions. These results were published in the July print issue of Antimicrobial Agents and Chemotherapy. The findings suggest tedizolid, if approved, could potentially be taken with commonly prescribed medicines such as many antidepressants, whose use is limited with agents that inhibit MAO. Some other antibiotics are associated with rare but significant neurological adverse events when used with such agents.